FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to ophthalmology, and is intended to create a toxic model of optic nerve atrophy for the purpose of subsequent study of the pathological process, development of methods for diagnosis and treatment. To do this, within 24 hours prior to the introduction of methanol, aminophylline is administered orally to rats per the weight of the experimental animal at a concentration of 10 μg/kg 3 times a day. The last dose of Aminophylline is made 8 hours before the injection of methanol solution. Further, by injection into the retrobulbar space of the rat, a 92% methanol solution diluted with 0.9% sodium chloride solution in a ratio of 1:1 is injected. After the injection of methanol over the next 24 hours, Aminophylline is administered orally based on the weight of the experimental animal at a concentration of 10 μg/kg 3 times a day, with the first administration being carried out 2 hours after the injection.
EFFECT: invention provides reliably produced optic nerve atrophy caused by toxic effect of methanol metabolites on optic nerve fibers.
1 cl, 6 dwg, 1 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
TETRAPEPTIDE STIMULATING EYE RETINA FUNCTION, PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD OF ITS USING | 2000 |
|
RU2161982C1 |
AGENT RECOVERING RETINA EYE FUNCTION | 1993 |
|
RU2073518C1 |
METHOD OF SIMULATING RETINAL PIGMENT EPITHELIUM ATROPHY | 2019 |
|
RU2709247C1 |
METHOD FOR SIMULATING DIABETIC MACULAR NEOVASCULARISATION | 2012 |
|
RU2504844C1 |
METHOD FOR PREVENTING ISCHEMIC NEUROPATHY OF THE OPTIC NERVE BY CARBAMYLATED DARBEPOETIN IN EXPERIMENT | 2017 |
|
RU2643579C1 |
METHOD FOR SIMULATING PARTIAL OPTIC ATROPHY | 2009 |
|
RU2399100C1 |
AGENT INHIBITING ANGIOGENESIS IN VISUAL ORGAN DISEASE | 2001 |
|
RU2177801C1 |
ANTIDOTE COMPOSITION FOR TREATING POISONING WITH METHYL ALCOHOL AND ETHYLENE GLYCOL | 2019 |
|
RU2692930C1 |
BDNF-BASED (BRAIN-DERIVED NEUROTROPHIC FACTOR) OPHTHALMIC PREPARATIONS AND USING THEM | 2010 |
|
RU2564920C2 |
BIOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION IN THE FORM OF STERILE AQUEOUS DISPERSION FOR CONJUNCTIVAL IN THE FORM OF DROPS AND SUBJUNCTIVAL, PARA -, RETROBULBAR INJECTION ADMINISTRATION IN THE CONDUCTED THERAPIES OF VASCULAR AND DYSMETABOLIC OPHTHALMOLOGICAL DISEASES | 2021 |
|
RU2771678C1 |
Authors
Dates
2022-12-20—Published
2022-06-14—Filed